Navigation Links
REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO
Date:5/28/2008

Seven Abstracts Accepted for Presentation at ASCO

SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) will hold an investor and analyst briefing in conjunction with the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) from 6:00 p.m. to 8:00 p.m. CT on Monday, June 2, 2008.

Participants:

-- George A. Scangos, PhD, President and Chief Executive Officer

-- Michael M. Morrissey, PhD, President of Research and Development

-- Gisela M. Schwab, MD, Executive Vice President and Chief Medical

Officer

Topics:

-- XL184 (targets: MET, VEGFR2, RET)

-- XL147 (targets: PI3K)

-- XL765 (targets: PI3K, mTOR)

-- XL647 (targets: EGFR, HER2, VEGFR2)

-- XL880* (targets: MET, VEGFR2)

-- XL281 (targets: RAF)

* XL880 was selected by GlaxoSmithKline in December 2007 for further

development and commercialization.

The event will be webcast and may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

An archived replay of this webcast will be available until 9:00 p.m. PT/12:00 a.m. ET on July 2, 2008. Access numbers for this replay are: 1-888-286-8010 (domestic) and +1-617-801-6888 (international); the replay passcode is: 42662164.

ASCO Presentations

Saturday, May 31

-- XL647 (EGFR, HER2, VEGFR2) -- Poster & Discussion

"A phase 1 study of XL647, an EGFR, HER2, VEGFR2 inhibitor,

administered orally daily to patients (pts) with advanced solid

malignancies (ASM)"

Day: Saturday, May 31

Session: Developmental Therapeutics: Molecular Therapeutics

Time (Poster): 8 a.m.-noon Location: W375e Lobby

Time (Discussion): Noon-1 p.m. Location: W375a

Poster Number: 5 Abstract Number: 3528

Presenter: Heather A. Wakelee, MD

-- XL880* (MET, VEGFR2) -- Poster

"A phase 2 study of the dual MET/VEGFR2 inhibitor GSK1363089 (XL880) in

patients with papillary renal carcinoma (PRC)"

Day: Saturday, May 31

Session: Genitourinary Cancer

Time: 8 a.m.-noon

Location: S Hall A1

Poster Number: 5G Abstract Number: 5103

Presenter: Ramiprasad Srinivasan, MD, PhD

-- XL765 (PI3K, mTOR) -- Oral Presentation

"A phase 1 dose-escalation study of the safety, pharmacokinetics (PK),

and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765,

administered orally to patients (pts) with advanced solid tumors"

Day: Saturday, May 31

Session: PI-3 Kinase/mTOR Directed Agents

Time: 1:45-2:15 pm

Location: W375a

Abstract Number: 3510

Presenter: Kyriakos Papadopoulis, MD

* XL880 was selected by GlaxoSmithKline in December 2007 for further

development and commercialization.

Sunday, June 1

-- XL184 (RET, MET, VEGFR2) -- Oral Presentation

"A phase 1 study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in

patients (pts) with advanced malignancies, including pts with medullary

thyroid cancer (MTC)"

Day: Sunday, June 1

Session: Developmental Therapeutics: Molecular Therapeutics

Time: 10-10:15 a.m.

Location: W375a

Abstract Number: 3522

Presenter: Ravi Salgia, MD, PhD

-- XL647 (EGFR, HER2, VEGFR2) -- Poster

"Activity of XL647 in clinically selected NSCLC patients (pts) enriched

for the presence of EGFR mutations: Results from phase 2"

Day: Sunday, June 1

Session: Lung Cancer-Metastatic

Time: 2-6 p.m.

Location: S Hall A1

Poster Number: 42H Abstract Number: 8053

Presenter: Naiyer A Rizvi, MD

Monday, June 2

-- XL647 (EGFR, HER2, VEGFR2) - Poster & Discussion

"Activity and tolerance of XL647 in NSCLC patients with acquired

resistance to EGFR-TKIs: Preliminary results of a phase 2 trial"

Day: Monday, June 2

Session: Lung Cancer -- Metastatic

Time (Poster): 8 a.m.-noon Location: W375e Lobby

Time (Discussion): Noon-12:15 p.m. Location: W375d

Poster Number: 9 Abstract Number: 8028

Presenter: Vincent A. Miller, MD

-- XL880* (MET, VEGFR2) -- Poster

"Preliminary activity of GSK1363089 (XL880), a dual MET/VEGFR2

inhibitor, in MET amplified poorly differentiated gastric cancer

(PDGC): Interim results of a multicenter phase 2 study"

Day: Monday, June 2

Session: Gastrointestinal (Noncolorectal) Cancer

Time: 8 a.m.-noon

Location: S Hall A1

Poster Number: 33D Abstract Number: 4572

Presenter: Minaxi P. Jhawer, MD

* XL880 was selected by GlaxoSmithKline in December 2007 for further

development and commercialization.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Exelixis and the Exelixis logo are registered U.S. trademarks.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
2. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
3. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
4. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
5. Exelixis Announces Closing of Public Offering of Common Stock
6. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
7. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
8. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
9. Exelixis Sells 80% Stake in Artemis to Taconic
10. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
11. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... Participants of ... a high-performance fume hood. Along with the advantages and disadvantages of ductless, filtered ... ducted hoods in the laboratory. , Attendees will learn from an industry expert ...
(Date:9/19/2017)... ... ... Biopharma ’s CEO and founder, Dr. Bob Harman DVM, MPVM, is featured in an interview ... Rising Tide". Dr. Harman and Dr. Riordan met in 2003 and have remained in ... of stem cell therapy and a fast friendship was formed. , Dr. Harman has been ...
(Date:9/19/2017)... Pleasanton, Calif. and Washington, D.C. (PRWEB) , ... ... ... to delivering rapid care during an biological outbreak is about to be eliminated, ... When asked what makes ExcitePCR’s FireflyDX™ technologies different than other pathogen ...
(Date:9/19/2017)... ... September 19, 2017 , ... Avomeen Analytical ... recipients of its 2017 Science Student Award. The scholarship program is dedicated to ... community service defray the costs of obtaining their science education. , Avomeen began ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):